Nektar Therapeutics has launched a Phase 2 study of the opioid analgesic NKTR-181, according to a company release.
NKTR-181 is designed to have a slow rate of entry into the brain and reduce side effects such as sedation and respiratory depression. The double-blind, placebo-controlled clinical study will assess the safety and tolerability of the drug in patients with moderate to severe chronic pain from osteoarthritis of the knee.
The study will enroll approximately 200 patients.
Pain Specialist Dr. David Cheng Joins Midwest Orthopaedics
Middle Fork Surgery Center Visited by Oregon's Co-Speaker of the House
NKTR-181 is designed to have a slow rate of entry into the brain and reduce side effects such as sedation and respiratory depression. The double-blind, placebo-controlled clinical study will assess the safety and tolerability of the drug in patients with moderate to severe chronic pain from osteoarthritis of the knee.
The study will enroll approximately 200 patients.
Related Articles on Pain Management:
Relmada Raises $3M to Develop LevoCap PainkillerPain Specialist Dr. David Cheng Joins Midwest Orthopaedics
Middle Fork Surgery Center Visited by Oregon's Co-Speaker of the House